Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Lucatumumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Lucatumumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Lucatumumab. |
| Estrone | Estrone may increase the thrombogenic activities of Lucatumumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Lucatumumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Lucatumumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Lucatumumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Lucatumumab. |
| Estriol | Estriol may increase the thrombogenic activities of Lucatumumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Lucatumumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Lucatumumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Lucatumumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Lucatumumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Lucatumumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lucatumumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Lucatumumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Lucatumumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Lucatumumab. |
| Equol | Equol may increase the thrombogenic activities of Lucatumumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Lucatumumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Lucatumumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Lucatumumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Lucatumumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Lucatumumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Lucatumumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Lucatumumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Lucatumumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Lucatumumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Lucatumumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Lucatumumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Lucatumumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lucatumumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Lucatumumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Lucatumumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Lucatumumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lucatumumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lucatumumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Lucatumumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lucatumumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Lucatumumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Lucatumumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Lucatumumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lucatumumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lucatumumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Lucatumumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lucatumumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lucatumumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Lucatumumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lucatumumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Lucatumumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Lucatumumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Lucatumumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lucatumumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lucatumumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Lucatumumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Lucatumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Lucatumumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Lucatumumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Lucatumumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Lucatumumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Lucatumumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Lucatumumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Lucatumumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Lucatumumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Lucatumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Lucatumumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Lucatumumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Lucatumumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Lucatumumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Lucatumumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Lucatumumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Lucatumumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Lucatumumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Lucatumumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Lucatumumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Lucatumumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Lucatumumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Lucatumumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Lucatumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Lucatumumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Lucatumumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Lucatumumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Lucatumumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Lucatumumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Lucatumumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Lucatumumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Lucatumumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lucatumumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Lucatumumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Lucatumumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Lucatumumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Lucatumumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Lucatumumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Lucatumumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Lucatumumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Lucatumumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Lucatumumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Lucatumumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Lucatumumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Lucatumumab. |